Status:
COMPLETED
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
Lead Sponsor:
UCB Pharma SA
Conditions:
Epilepsy, Tonic-clonic
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
Eligibility Criteria
Inclusion
- Subjects with a confirmed diagnosis of epilepsy.
- Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures
- Subjects having participated in the previous double-blind monotherapy trial (N01061 \[NCT00150735\] or N01093 \[NCT00150787\]).
- Male/female subjects (\>= 16 years).
Exclusion
- \- Need for an additional Antiepileptic Drug (AED).
Key Trial Info
Start Date :
August 10 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2007
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00150813
Start Date
August 10 2005
End Date
May 29 2007
Last Update
November 21 2018
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Beroun, Czechia
2
Brno, Czechia
3
České Budějovice, Czechia
4
Prague, Czechia